Results 231 to 240 of about 50,442 (246)
Some of the next articles are maybe not open access.
Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells
Experimental Hematology, 2007Preclinical and clinical trials are investigating the potential of T cells genetically modified to express a first-generation CD19-specific chimeric antigen receptor (CAR), designated CD19R, for adoptive immunotherapy of B-lineage leukemias and lymphomas.
Tontanai, Numbenjapon +5 more
openaire +2 more sources
Current Research in Translational Medicine
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
CD19: Lowering the Threshold for Antigen Receptor Stimulation of B Lymphocytes
Science, 1992Lymphocytes must proliferate and differentiate in response to low concentrations of a vast array of antigens. The requirements of broad specificity and sensitivity conflict because the former is met by low-affinity antigen receptors, which precludes achieving the latter with high-affinity receptors.
R H, Carter, D T, Fearon
openaire +2 more sources
Generation of CD19-Targeted Chimeric Antigen Receptor T Cells.
Archives of Iranian medicine, 2020Current advancements in the field of chimeric antigen receptor (CAR) therapy, particularly U.S. FDA approval of Kymriah and Yescarta, heralds a new era of cancer treatment. This rapid progress in technology has urged more countries and institutions to keep pace with the fast-growing and developing technology of producing CAR T cell-based therapies in ...
Jafar, Kiani +6 more
openaire +1 more source
Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor
Blood, 2010Abstract Abstract 3262 Relapsed acute lymphoblastic leukemia (ALL) remains a difficult challenge for both pediatric and adult patients. Chimeric antigen receptors (CARs) are genetically engineered molecules expressed in transduced T lymphocytes. CARs express both a target binding motif and TCRzeta signals needed for T cell
Daniel W. Lee +4 more
openaire +1 more source
CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma
Journal of Clinical Oncology, 2019PURPOSE Anti-CD19–directed chimeric antigen receptor (CAR) T-cell therapy has had a resounding effect on the treatment of chemotherapy-insensitive aggressive B-cell non-Hodgkin lymphoma (B-NHL). There are now two US Food and Drug Administration (FDA)–approved products available for treating these patients, and a third product is expected to be approved
openaire +2 more sources
CD19 chimeric antigen receptor‐T cell therapy in murine immune thrombocytopenia
British Journal of HaematologySummary Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by antiplatelet autoantibodies, with many patients refractory or relapsing on conventional treatments. GPIbα, an important autoantigen in ITP, is notably linked to refractoriness, highlighting the need for novel treatments.
Fengjiao Han +10 more
openaire +2 more sources
Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy
Annals of Hematology, 2022James A. Davis +5 more
openaire +2 more sources